• NEWS . 17 Aug 2020
  • Abnormal glucose tolerance linked to increased MACE risk among patients with MI

  • Patients with acute myocardial infarction (MI) have a high prevalence of newly discovered abnormal glucose tolerance (AGT), according to results from a meta-analysis. 

    Data were extracted from prospective studies in patients with acute MI without known history of diabetes; AGT diagnosed using fasting plasma glucose, 2-hour oral glucose tolerance test, or HbA1c; and incidence of major adverse cardiac events (MACE) and/or all-cause mortality in newly discovered AGT.

    In these 19 studies (N=41,509, median follow-up 3.1 years), the prevalence of newly discovered AGT was 48.4% (95% confidence interval [CI], 40.2–56.6). Prediabetes had a higher mortality risk than normal glucose tolerance (NGT) (hazard ratio [HR], 1.36; 95% CI, 1.13–1.63; p<0.001) and MACE (HR, 1.42; 95% CI, 1.20–1.68; p<0.001). Also, newly diagnosed diabetes had higher mortality risk than NGT (HR, 1.74; 95% CI, 1.48–2.05; p<0.001) and MACE (HR, 1.54; 95% CI, 1.23–1.93; p<0.001).

    The study findings underscore the need for aggressive risk reduction strategies in this population, especially in those with prediabetes. 

    Laichuthai N, et al. Newly discovered abnormal glucose tolerance in patients with acute myocardial infarction and cardiovascular outcomes: A meta-analysis. Diabetes Care 2020;43:1958-1966.